Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.35 (
matrix metalloproteinase 9
)
2,207
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Although the expression of the metastases-associated gene
MTA1
correlates with tumor metastases, its role in regulating type IV collagenase expression is unknown. Enforced
MTA1
expression in HT1080 cells reduced basal and 12-myristate 13-acetate-induced
92-kDa type IV collagenase
(MMP-9) protein/mRNA levels. DNase I hypersensitivity and PstI accessibility assays revealed multiple regions of the MMP-9 promoter (-650/-450 and -120/+1), showing reduced hypersensitivity in the
MTA1
-expressing cells. Chromatin immunoprecipitation assays demonstrated
MTA1
binding to the distal region, which spans several regulatory cis elements. Co-immunoprecipitation and chromatin immunoprecipitation assay experiments revealed histone deacetylase 2 (HDAC2)-
MTA1 protein
-protein interactions and the
MTA1
-dependent recruitment of HDAC2 to the distal MMP-9 promoter region, yielding diminished histone H3/H4 acetylation. However, HDAC2 binding and H3/H4 acetylation at the proximal MMP-9 region were unaffected by
MTA1
expression. Furthermore, trichostatin treatment only partially relieved
MTA1
-repressed MMP-9 expression, indicating a HDAC-insensitive component possibly involv ing the nucleosome-remodeling Mi2 activity, which was recruited to the promoter by
MTA1
. In summary, (a) MMP-9 adds to a short list of
MTA1
-regulated genes, which so far only includes c-myc and pS2, and (b)
MTA1
binds to the MMP-9 promoter, thereby repressing expression of this type IV collagenase via histone-dependent and independent mechanisms.
...
PMID:Repression of 92-kDa type IV collagenase expression by MTA1 is mediated through direct interactions with the promoter via a mechanism, which is both dependent on and independent of histone deacetylation. 1243 81